Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Rheumatoid Arthritis (RA)"

The Rescue: Moving RA Patients from Adalimumab to Baricitinib

Lara C. Pullen, PhD  |  June 25, 2019

The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…

Biological DMARDs in Elderly RA Patients: Use, Maintenance & Discontinuation

Natasha Yetman  |  June 17, 2019

A study comparing seven biologic DMARDs in RA patients aged 65 years and older found abatacept had the highest retention rate and the lowest discontinuation rate…

New Research Examines the Use of Natural Dietary Supplements by RA Patients

Arthritis Care & Research  |  June 4, 2019

The popularity of natural dietary supplements has grown worldwide, with many adults using them to manage musculoskeletal conditions. But for RA patients, little is known about the risk of side effects and potential adverse drug interactions when taking these supplements with standard RA therapies. New research examined the supplement use patterns of RA patients…

Tofacitinib + Methotrexate: 2-Year Clinical, Radiographic & Safety Outcomes

Michele B. Kaufman, PharmD, BCGP  |  June 4, 2019

In a 24-month clinical trial, tofacitinib proved safe and effective in combination with methotrexate in adult patients with RA…

Predictors of RA Flare After Total Joint Arthroplasty

Carina Stanton  |  May 20, 2019

At the time of total joint arthroplasty, RA disease activity has been shown to better predict postoperative flare than medication management…

How Does Health Literacy Affect the Patient Global Assessment?

Arthritis Care & Research  |  May 8, 2019

For RA patients, a low score on the patient global assessment of disease activity as measured by a visual analog scale (PGA-VAS) is necessary to confirm remission. However, limited patient health literacy combined with the complexity of the scale may result in discrepancies between the PGA-VAS and provider assessments of disease activity. New research examined the patient perspective on the PGA-VAS and its connections to health literacy and disease state…

Characterization of Autoreactive B Cells in Patients with SLE & RA

Lara C. Pullen, PhD  |  May 6, 2019

Antibody-secreting cells are important for the pathophysiology of SLE and RA, but researchers have been unable to determine how these cells are activated. A new technique is able to distinguish between naïve autoreactive B cells and established antibody secreting cells…

Chronic Opioid Use in Rheumatoid Arthritis: Prevalence & Predictors

Arthritis & Rheumatology  |  May 1, 2019

Over the past decade, physicians, patients and policy makers have expressed increasing concern about the high frequency of opioids being prescribed and the association between opioid use and poor outcomes. Rates of opioid prescriptions in the general population rose considerably from the 1990s through 2010, with a plateau in the early 2010s. In 2015, 38%…

More Data for Treat to Target: Post-Hoc Analysis of Large RA Clinical Trials Supports Treat-to-Target Recommendations

Gretchen Henkel  |  April 17, 2019

A post-hoc analysis of data from two large clinical trials supports treat-to-target recommendations for patients with rheumatoid arthritis. The research found baseline disease activity was the strongest predictor of a patient’s insufficient response to initial therapy at six months…

Galectin-3 May Be a Biomarker for Cardiovascular Disease in RA

Carina Stanton  |  March 25, 2019

Galectin-3 may have potential as a biomarker for the early onset of cardiovascular disease in RA patients, potentially enabling early intervention and deferring the cardiovascular risks associated with RA…

  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 30
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences